The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer side effects.

Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed ​ earlier this year. The deal has paid off as Karuna’s lead asset was approved ​ last week by the US FDA.

The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. This innovative medication marks a significant

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.

The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion.

"This drug takes the first new approach to schizophrenia treatment in decades," Tiffany Farchione, a top official in the US Food and Drug Administration (FDA), said in a statement Thursday. "This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed,